Company Profile
Mereo BioPharma Stock Price, News & Catalysts
- Ticker:
- MREO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
0.37 USD (-8.73%)
Close
Last updated: October 1, 2026
54.2M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, MREO closed down 8.73% at $0.3669. No new same-company headline was identified in the current news window.
Company overview
Rare Disease Company
Mereo BioPharma develops and partners therapies for rare diseases.
Setrusumab
Setrusumab is an anti-sclerostin antibody partnered with Ultragenyx for osteogenesis imperfecta. Mereo and its partner are evaluating whether subgroup evidence supports a pediatric regulatory path after global Phase 3 results.
Vantictumab
Vantictumab is a Wnt-pathway antibody licensed to āshibio for development in autosomal dominant osteopetrosis type 2.
Future catalysts
- Mereo plans to update investors after regulatory discussions regarding a potential pediatric path for setrusumab.
- A Phase 2 study of vantictumab in autosomal dominant osteopetrosis type 2 is expected to begin in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mereo BioPharma (MREO)?
Mereo BioPharma (MREO) most recently closed at 0.37 USD, a -8.73% move versus the previous session.
What is the market cap of Mereo BioPharma (MREO)?
Mereo BioPharma currently has a market capitalization of 54.2M USD on BioPharmSignal.
What does Mereo BioPharma do?
Rare Disease Company Mereo BioPharma develops and partners therapies for rare diseases. Setrusumab Setrusumab is an anti-sclerostin antibody partnered with Ultragenyx for osteogenesis imperfecta. Mereo and its partner are evaluating whether subgroup evidence supports a pediatric regulatory path after global Phase 3 results. Vantictumab Vantictumab is a...
On which exchange is MREO stock listed?
Mereo BioPharma (MREO) is associated with NASDAQ, United Kingdom, Biopharma.
What is setrusumab?
Mereo plans to update investors after regulatory discussions regarding a potential pediatric path for setrusumab.
Which conditions is Mereo BioPharma targeting with setrusumab?
Mereo BioPharma is associated with rare disease based on its company overview and current catalyst commentary.
How does Mereo BioPharma describe recent progress with setrusumab?
Mereo plans to update investors after regulatory discussions regarding a potential pediatric path for setrusumab.
What is vantictumab?
Vantictumab Vantictumab is a Wnt-pathway antibody licensed to āshibio for development in autosomal dominant osteopetrosis type 2.